Bio-Techne Corporation (TECH) Stock Score, Valuation & Financial Research
Bio-Techne Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for TECH
Bio-Techne Corporation currently has a Wall Street Score of 33/100. The stored market price is $72.12. Its financial score is 30/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Bio-Techne Corporation does
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufact
TECH financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $72.12
- Market capitalization:
- $11.29B
- Revenue:
- $1.21B
- Net income:
- $109.6M
- Free cash flow:
- $256.6M
- Cash:
- $209.8M
- Total debt:
- $290.3M
- EPS:
- 0.47
- P/E ratio:
- 153.4x
- Financial score:
- 30/100
- Valuation score:
- 0/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $256.6M, showing positive cash generation.
- The balance sheet shows $209.8M of cash versus $290.3M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TECH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.